Indoleamine 2,3-Dioxygenase (IDO) Expression Is an Independent Prognostic Marker in Esophageal Adenocarcinoma
| Autor: | Alexander Quaas, Hakan Alakus, Max Kraemer, Arnulf H. Hoelscher, Christiane Bruns, Wolfgang Schröder, Heike Loeser, Reinhard Buettner, Thomas Zander, Philipp Lohneis, Florian Gebauer |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Male
Article Subject Esophageal Neoplasms medicine.medical_treatment Immunology Gene Expression Adenocarcinoma 03 medical and health sciences 0302 clinical medicine Breast cancer Gene expression medicine Biomarkers Tumor Immunology and Allergy Humans Indoleamine-Pyrrole 2 3 -Dioxygenase Neoplasm Metastasis Indoleamine 2 3-dioxygenase Neoadjuvant therapy 030304 developmental biology Aged Neoplasm Staging Proportional Hazards Models Aged 80 and over 0303 health sciences Tumor microenvironment business.industry Proportional hazards model General Medicine Middle Aged RC581-607 medicine.disease Prognosis Immunohistochemistry Immune checkpoint Neoadjuvant Therapy 030220 oncology & carcinogenesis Cancer research Female Immunologic diseases. Allergy business Biomarkers Research Article |
| Zdroj: | Journal of Immunology Research, Vol 2020 (2020) Journal of Immunology Research |
| ISSN: | 2314-7156 2314-8861 |
| Popis: | Background. Indoleamine 2,3-dioxygenase (IDO) is an interferon-inducible immune checkpoint expressed on tumor-infiltrating lymphocytes (TILs). IDO is known as a poor prognostic marker in esophageal squamous cell cancer, while a positive effect was shown for breast cancer. A comprehensive analysis of IDO expression in a well-defined cohort of esophageal adenocarcinoma (EAC) is missing. Methods. We analyzed 551 patients with EAC using single-protein and multiplex immunohistochemistry as well as mRNA in situ technology for the expression and distribution of IDO on subtypes of TILs (INF-γ mRNA and CD4- and CD8-positive T lymphocytes). Results. IDO expression on TILs was seen in up to 59.6% of tumors, and expression on tumor cells was seen in 9.2%. We found a strong positive correlation of IDO-positive TILs, CD3-positive T lymphocytes, and INF-γ mRNA-producing TILs in the tumor microenvironment of EACs showing significantly better overall survival (47.7 vs. 22.7 months, p<0.001) with emphasis on early tumor stages (pT1/2: 142.1 vs. 37.1 months, p<0.001). In multivariate analysis, IDO is identified as an independent prognostic marker. Conclusions. Our study emphasizes the importance of immunomodulation in EAC marking IDO as a potential biomarker. Beyond this, IDO might indicate a subgroup of EAC with an explicit survival benefit. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text